Evidence map›Paper›PMID 39117782›Full record

ArticleClinical journal of gastroenterology2024

A small bowel adenocarcinoma harboring a DDR2 mutation in a celiac patient.

Ludovica Mollica, Erica Quaquarini, Annalisa Schiepatti, Erica Travaglino, Francesca Antoci, Alessandro Vanoli, Giovanni Arpa, Federico Biagi, Laura Deborah Locati

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ludovica Mollica *Medical Oncology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Via Maugeri, 10 27100, Pavia, Italy.
Erica Quaquarini *Medical Oncology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Via Maugeri, 10 27100, Pavia, Italy. erica.quaquarini@gmail.com.ORCID http://orcid.org/0000-0001-9099-5352
Annalisa SchiepattiDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
Erica TravaglinoAnatomic Pathology Unit, Fondazione IRCCS San Matteo Hospital, Pavia, Italy.
Francesca AntociAnatomic Pathology Unit, Fondazione IRCCS San Matteo Hospital, Pavia, Italy.
Alessandro VanoliAnatomic Pathology Unit, Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Giovanni ArpaAnatomical Pathology Unit of Pavia Institute, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
Federico BiagiDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
Laura Deborah LocatiMedical Oncology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Via Maugeri, 10 27100, Pavia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present the case of a 62-year-old man with a history of celiac disease and IgA deficiency, following a strict gluten-free diet that was admitted to our hospital for recurrent abdominal pain, fatigue and melena. Esophagogastroduodenoscopy and colonoscopy with biopsies were normal. A video-capsule endoscopy was performed and revealed a sub-stenosing, vegetating, and bleeding lesion in the first jejunal loop. He underwent laparotomic surgery with resection of the involved segment with loco-regional lymphadenectomy. The pathological report described a poorly differentiated adenocarcinoma of the jejunum, stage IIIA (pT3pN1). Analysis of next-generation sequencing (NGS) of DNA on the surgical sample revealed a likely pathogenetic variant in exon 15 of the DDR2 gene (c.2003G > A) and a TP53 non-frame-shift deletion (c.585_602del). Considering the risk of recurrence, he was candidate to 6 months of adjuvant chemotherapy with platinum salt and fluoropyrimidine. Thirty-eight months after the diagnosis, the patient is still disease free and in good clinical condition. This is the first described case of SBA with DDR2 mutation. Considering the limited therapeutic options beyond surgery for SBA, molecular analyses could become promising for the search for potential targetable alterations for treatments with new available drugs.

Indexed as

AdenocarcinomaCeliac DiseaseDiscoidin Domain Receptor 2Jejunal NeoplasmsMutationCapsule EndoscopyHumansMaleMiddle AgedDDR2 protein, humanDiscoidin Domain Receptor 2Celiac diseaseDDR2 mutationSmall bowel adenocarcinomaTP53 mutation

Identifiers

PMID39117782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.